Posts tagged VRX


Valeant Pharmaceuticals Intl Inc (VRX) Gets a Price Target Trim on Uncertainty Circling Legal Liabilities

Deutsche Bank’s Gregg Gilbert is concerned about the unpredictability of VRX’s legal hurdles that lie ahead.

Read more

Billionaire Israel Englander’s Surprising Q3 Moves In Biotech: Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Valeant Pharmaceuticals Intl Inc (VRX), ACADIA Pharmaceuticals Inc. (ACAD)

Israel “Izzy” Englander isn’t afraid to go against the market on TEVA, VRX and ACAD.

Read more

Is There Still a Glimmer of Hope for Valeant Pharmaceuticals Intl Inc (VRX)?

BMO stays on the sidelines as VRX still faces headwinds, but praises key “headway” in growth.

Read more

Here’s Why Analyst David Maris Is a Party Pooper on Valeant Pharmaceuticals Intl Inc (VRX) After 3Q Turnout

Though investor sentiment has turned positive on VRX after 3Q earnings, Wells Fargo makes a bearish case.

Read more

Valeant Pharmaceuticals Intl Inc (VRX): Weaknesses Still Linger After the Solid 3Q Show

Ram Selvaraju needs to see more proof of VRX’s pipeline staying power and ability to yield gains.

Read more

Analyst Says More Work to Be Done in Valeant Pharmaceuticals Intl Inc (VRX) Turnaround After Q3 Success

BTIG’s Tim Chiang believes a lot hinges on the Vyzulta launch for VRX to stage a solid comeback.

Read more

Valeant Pharmaceuticals Intl Inc (VRX) 3Q Beat Is a Case of Execution Done Right, Says Louise Chen

It’s a win for the bulls as VRX’s execution and robust growth down the line bode well for the giant’s future.

Read more

Valeant Pharmaceuticals Intl Inc’s (VRX) Situation Remains Dire: Irina Rivkind Koffler

Is Valeant on track to overcome financial troubles? Mizuho’s Irina Rivkind Koffler remains unconvinced.

Read more

This Bear Believes Valeant Pharmaceuticals Intl Inc (VRX) Played It Smart in Letting Sprout Pharma Go

David Maris: Valeant is getting rid of an opportunity that would never translate to money.

Read more

A Bear Predicts: Valeant Pharmaceuticals Intl Inc (VRX) Is Going to Lower Its Expectations into 2018

Irina Rivkind Koffler warns VRX will face the brunt of various large scope headwinds.

Read more